Palifermin biosimilar - Nanogen BiopharmaceuticalAlternative Names: Keratinocyte growth factor - Nanogen
Latest Information Update: 19 Mar 2014
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Chemoprotectants; Fibroblast growth factors
- Mechanism of Action Fibroblast growth factor replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Stomatitis
Most Recent Events
- 19 Mar 2014 Early research in Stomatitis in Vietnam (IV)